Zobrazeno 1 - 10
of 601
pro vyhledávání: '"Hans, Lilja"'
Autor:
Chaoran Ma, Caroline Ericsson, Sigrid V. Carlsson, Hans Lilja, Adam Kibel, Rebecca E. Graff, Anna Plym, Edward Giovannucci, Lorelei A. Mucci, Mark A. Preston, Kathryn L. Penney
Publikováno v:
European Urology Open Science, Vol 50, Iss , Pp 27-30 (2023)
Men with a low prostate-specific antigen (PSA) level (60 yr) owing to their low risk of aggressive prostate cancer (PCa). However, there is a subset of men who develop lethal PCa despite low baseline PSA. We investigated how a PCa polygenic risk scor
Externí odkaz:
https://doaj.org/article/ba3756fa51bd4d1882995eb070168f12
Autor:
Anssi Auvinen, Ola Bratt, Jonas Hugosson, Monique J Roobol, Hans Lilja, Rebecka Arnsrud Godtman, Mikael Hellström, Jonas Wallström
Publikováno v:
BMJ Oncology, Vol 2, Iss 1 (2023)
Long-term screening with serum prostate-specific antigen (PSA) and systematic prostate biopsies can reduce prostate cancer mortality but leads to unacceptable overdiagnosis. Over the past decade, diagnostic methods have improved and the indolent natu
Externí odkaz:
https://doaj.org/article/fca1a2bf47ac4ba2995db0a9bc6f38d3
Autor:
Jacob Fredsøe, Martin Rasmussen, Amy L. Tin, Andrew J. Vickers, Michael Borre, Karina D. Sørensen, Hans Lilja
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)
Abstract Elevated prostate-specific antigen (PSA) levels often lead to unnecessary and possibly harmful transrectal ultrasound guided biopsy, e.g. when the biopsy is negative or contains only low-grade insignificant cancer, unlikely to become symptom
Externí odkaz:
https://doaj.org/article/1fba00dcdc114233a0873069587c4c22
Autor:
Robert J. Klein, Emily Vertosick, Dan Sjoberg, David Ulmert, Ann-Charlotte Rönn, Christel Häggström, Elin Thysell, Göran Hallmans, Anders Dahlin, Pär Stattin, Olle Melander, Andrew Vickers, Hans Lilja
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-8 (2022)
Abstract Polygenic risk scores (PRS) for prostate cancer incidence have been proposed to optimize prostate cancer screening. Prediction of lethal prostate cancer is key to any stratified screening program to avoid excessive overdiagnosis. Herein, PRS
Externí odkaz:
https://doaj.org/article/5f0a0b867c3d40ad97478098664fd2bd
Autor:
Anson Ku, Jacob Fredsøe, Karina D. Sørensen, Michael Borre, Mikael Evander, Thomas Laurell, Hans Lilja, Yvonne Ceder
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Molecular profiling of extracellular vesicles (EVs) offers novel opportunities for diagnostic applications, but the current major obstacle for clinical translation is the lack of efficient, robust, and reproducible isolation methods. To bridge that g
Externí odkaz:
https://doaj.org/article/3ab2d8b36f5f44879dba4a21caac9055
Autor:
Michael R. McDevitt, Daniel L. J. Thorek, Takeshi Hashimoto, Tatsuo Gondo, Darren R. Veach, Sai Kiran Sharma, Teja Muralidhar Kalidindi, Diane S. Abou, Philip A. Watson, Bradley J. Beattie, Oskar Vilhemsson Timmermand, Sven-Erik Strand, Jason S. Lewis, Peter T. Scardino, Howard I. Scher, Hans Lilja, Steven M. Larson, David Ulmert
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Radionuclides that emit alpha particles (charged helium nuclei) are currently used clinically to treat cancers including prostate cancer. Here, the authors combine a humanized antibody to an alpha particle emitter, specifically to target a downstream
Externí odkaz:
https://doaj.org/article/02a356c6cc14425c8da1a1e7764743bc
Autor:
Linda Kachuri, Thomas J. Hoffmann, Yu Jiang, Sonja I. Berndt, John P. Shelley, Kerry Schaffer, Mitchell J. Machiela, Neal D. Freedman, Wen-Yi Huang, Shengchao A. Li, Ryder Easterlin, Phyllis J. Goodman, Cathee Till, Ian Thompson, Hans Lilja, Stephen K. Van Den Eeden, Stephen J. Chanock, Christopher A. Haiman, David V. Conti, Robert J. Klein, Jonathan D. Mosley, Rebecca E. Graff, John S. Witte
Publikováno v:
Nature medicine, vol 29, iss 6
Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer-related PSA v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8082ab252bb355a5b5be38d07936b61d
https://escholarship.org/uc/item/08d3g24k
https://escholarship.org/uc/item/08d3g24k
Autor:
Christopher A. Haiman, David V. Conti, Hans Lilja, Loïc Le Marchand, Lynne R. Wilkens, Burcu F. Darst, Alisha Chou
Supplementary Figure from Association of Prostate-Specific Antigen Levels with Prostate Cancer Risk in a Multiethnic Population: Stability Over Time and Comparison with Polygenic Risk Score
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc39e8ca78114d7ca31ca3f265addb7
https://doi.org/10.1158/1055-9965.23099356
https://doi.org/10.1158/1055-9965.23099356
Autor:
Christopher A. Haiman, David V. Conti, Hans Lilja, Loïc Le Marchand, Lynne R. Wilkens, Burcu F. Darst, Alisha Chou
Background:Studies in men of European ancestry suggest prostate-specific antigen (PSA) as a marker of early prostate cancer development that may help to risk-stratify men earlier in life.Methods:We examined PSA levels in men measured up to 10+ years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77430d7b09fd5580774d2202e9bbc60e
https://doi.org/10.1158/1055-9965.c.6660313
https://doi.org/10.1158/1055-9965.c.6660313
Autor:
Francesco Pellegrino, Daniel D. Sjoberg, Amy L. Tin, Nicole E. Benfante, Alberto Briganti, Francesco Montorsi, Peter T. Scardino, James A. Eastham, Andrew J. Vickers, Hans Lilja, Vincent P. Laudone
Publikováno v:
World Journal of Urology.